Donald R. Coustan, MD is Professor Emeritus of Obstetrics and Gynecology at the Warren Alpert Medical School of Brown University. Dr. Coustan served as Obstetrician & Gynecologist-in-Chief at Women & Infants Hospital, Chace/Joukowsky Professor and Chair, Department of Ob/Gyn, Warren Alpert Medical School of Brown University from 1991 through 2008. From 2008 through 2017 he devoted his clinical time to the care of women with diabetes during pregnancy.
Dr. Coustan has published widely in the areas of diabetes and pregnancy and gestational diabetes. He served as Regional Director for North America of the HAPO study. Dr. Coustan has served as President of the Rhode Island Medical Society, and of the Society for Maternal-Fetal Medicine. He has served on the Board of Directors of the American Diabetes Association, and on the National Advisory Committee of the Robert Wood Johnson Clinical Scholars Program. He is past President of the American Gynecological and Obstetrical Society. He recently completed a term on the Professional Practice Committee of the American Diabetes Association.
Dr Martin Wolley is a Nephrologist with a research interest in resistant hypertension and primary aldosteronism. He completed his PhD with Professor Michael Stowasser in the Hypertension unit at the University of Queensland in this field, examining clinical and physiological aspects of primary aldosteronism. He is currently involved in a large collaborative project examining the physiological role of potassium in distal tubular sodium handling and hypertension and works clinically the Royal Brisbane and Women’s Hospital and the Princess Alexandra Hospital in Brisbane.
Megan R. Haymart, MD, is an Associate Professor of Medicine at the University of Michigan with a primary appointment in the Division of Metabolism, Endocrinology, and Diabetes and a secondary appointment in the Division of Hematology/Oncology. Dr. Haymart's research focuses on variation in the management of thyroid cancer with an emphasis on the role of patients, providers, and health systems in thyroid cancer diagnosis and treatment. She also studies thyroid cancer outcomes and the rise in thyroid cancer incidence. She is Principal Investigator of the NCI-funded R01 grant “Treatment Decision Making in Low-Risk Thyroid Cancer” and the AHRQ-funded R01 grant “Imaging Practices and Overdiagnosis of Thyroid Cancer”.
Dr. Haymart received her medical degree from Johns Hopkins University School of Medicine in 2002, completed internal medicine residency at Johns Hopkins Hospital in 2005, and then completed fellowship in endocrinology, diabetes and metabolism at the University of Wisconsin in 2007. In 2009, she joined the University of Michigan faculty as Assistant Professor of Medicine and in 2017 she was promoted to Associate Professor of Medicine. Dr. Haymart is involved in creating the National Comprehensive Cancer Network thyroid carcinoma guidelines, is on the Board of Directors for the American Thyroid Association, serves on the editorial board for the Journal of Clinical Oncology, and is Associate Editor for Thyroid.
Dr. Natalie E. Cusano is is the Director of the Bone Unit at Lenox Hill Hospital in the Division of Endocrinology. She received her undergraduate training at the Massachusetts Institute of Technology and her medical training at the Boston University School of Medicine. She completed her residency training in Internal Medicine at Beth Israel Deaconess Medical Center and her fellowship training in Endocrinology, Diabetes & Metabolism at the College of Physicians & Surgeons, Columbia University. She lists over 75 publications of original research, invited articles, chapters and abstracts in the field of metabolic bone disease. She is on the editorial board of Endocrine Practice
Professor Peter Trainer qualified in Edinburgh and continued with his higher training in London (St Bartholomew’s hospital); Aberdeen; Utrecht, Holland; and Portland, Oregon, USA. He was a senior lecturer at Barts before becoming a consultant endocrinologist at the Christie Hospital in 1998.
Professor Trainer is an active leader in the medical community. He has served on the senior executive committees of the Society for Endocrinology (UK), the American Endocrine Society and the European Society for Endocrinology. He chaired the programme organising committee for the European Congress of Endocrinology (2011) and the clinical programme of the American Endocrine congress in 2007. Professor Trainer has published extensively, with over 150 papers in peer-reviewed journals. He is also a sought after lecturer and teacher, Chair of the European Society for Endocrinology education committee, and he has served on the editorial boards of The Journal of Clinical Endocrinology and Metabolism, Clinical Endocrinology, Treatments in Endocrinology, and GH and IGF Research. His prime areas of research are diseases of the pituitary and adrenal glands, particularly Cushing’s syndrome and acromegaly.
Dr. Toth received his B.A. in Biochemistry from Princeton University and a Ph.D. in Biochemistry from Michigan State University. He graduated from Wayne State University School of Medicine and completed residency training in Family Medicine at the University of Iowa Hospitals and Clinics.
Dr. Toth is a diplomate of the American Board of Family Practice and the American Board of Clinical Lipidology. Dr. Toth is a member of Alpha Omega Alpha, the American College of Cardiology Foundation Council on Cardiovascular Disease Prevention, and the American Heart Association's Council on Lipoproteins, Lipid Metabolism, and Thrombosis.
Dr. Toth has authored and coauthored over two hundred twenty publications in medical and scientific journals and textbooks. He is Editor-in-Chief of the Year in Lipid Disorders (Atlas Publishing, Oxford, UK) and an Associate Editor for the Year Book of Endocrinology. He is coeditor with Antonio Gotto of the textbook, Comprehensive Management of High Risk Cardiovascular Patients (Taylor and Francis, New York) with Michael Davidson of Therapeutic Lipidology (Humana, Philadelphia), with Dominic Sica of Current Controversies in Dyslipidemia Management (Atlas Publishing, Oxford), with Kevin Maki of Practical Lipid Management (Wiley-Blackstone, London), with Christopher Cannon of Comprehensive Cardiovascular Care in the Primary Care Setting (Springer Humana, Philadelphia), and Domenic Sica of Clinical Challenges in Hypertension vols I and II (Clinical Publishing, Oxford, UK). He has lectured on many topics in cardiovascular medicine throughout the United States.
Steven E. Nissen MD, is Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. In 2006-2007 he served as President of the American College of Cardiology (ACC), the professional society representing American cardiologists.
His research has focused on application of intravascular ultrasound (IVUS) imaging to the assessment of progression and regression of coronary atherosclerosis. More recently, he has served as study chairman for large cardiovascular outcomes trials. Contributions to scientific literature include more than 400 journal articles and 60 book chapters. He is co-author of a book for patients with heart disease, Heart411 released by Crown Books on January 31, 2012.
Dr. Nissen works closely with pharmaceutical companies on the development of new therapies for cardiovascular disease, but maintains a longstanding policy of requiring companies to donate all related honoraria directly to charity so that he receives neither income, nor a tax deduction.
He has also written extensively on the subject of drug safety. In 2001, he co-authored the first manuscript that raised concerns about the safety of rofecoxib (Vioxx™), which was withdrawn from the market 3 years later. In 2007, he authored a manuscript that demonstrated that the widely used diabetes drug rosiglitazone (Avandia™) raised the risk of myocardial infarction, eventually leading in 2010 to withdrawal of the drug in Europe and severe restrictions in the US.
Dr. Nissen served as a member of the CardioRenal Advisory Panel of Food and Drug Administration (FDA) for 5 years, and Chairman the final year of his membership. He continues to serve as Advisor to several FDA committees as a “Special Government Employee”. In July 2008, while serving as guest member of the Endocrine and Metabolism Advisory Panel, he recommended a new approach for approval of diabetes drugs, which was ultimately adopted by the Agency in December 2008.
Dr. Nissen is also known for his role in public policy discussions, particularly in the area of drug safety. He has testified in both the Senate (Health Education and Labor Committee) and House of Representatives (Energy and Commerce Committee) on Food and Drug Administration (FDA) policy. He was actively involved in discussions with Congress on the FDA Amendments Act of 2007 that added additional regulatory authority for the Agency.
In 2007, Time Magazine selected Dr. Nissen as one of the world’s 100 most influential people. In 2015, he was named by Thompson-Reuters as one of the world’s most highly cited physician-scientists.
William T. Cefalu, MD, is Section Chief, Joint Diabetes, Endocrinology and Metabolism Program of the Louisiana State University School of Medicine/Pennington Biomedical Research Center, as well as the Douglas L. Manship, Sr., Professor of Diabetes at Pennington Biomedical Research Center of Louisiana State University System in Baton Rouge, Louisiana. Prior to his appointment at Pennington Biomedical Research Center, he served as Director of the Clinical Trials Unit at the University of Vermont College of Medicine.
Dr. Cefalu received his medical degree from Louisiana State University School of Medicine in New Orleans, Louisiana. He completed his residency and was Chief Resident at the University of California-Irvine Long Beach VA Medical Center. He completed a fellowship in Metabolism and Endocrinology at the UCLA Center for Health Sciences. He has served on the faculty at Tulane University School of Medicine and Wake Forest University School of Medicine, where he was Director of the Diabetes Comprehensive Care Programs. Dr. Cefalu’s research is active at both the clinical and basic levels. On a clinical level, he is interested in clinical interventions to improve the metabolic state of individuals with insulin resistance and type 2 diabetes. On a basic level, he is interested in cellular mechanisms for insulin resistance. In addition, Dr. Cefalu also serves as Director for an NIH-funded Center for the Study of Botanicals and Metabolic Syndrome at Pennington Biomedical Research Center.
Dr. Cefalu is published widely in journals, books, and book chapters and has edited several textbooks on the management of diabetes. He was a past Associate Editor for Diabetes Care and is currently an Associate Editor for Diabetes. He lectures both nationally and internationally.
Emirates Diabetes & Endocrine Congress (EDEC) is organized by Emirates Diabetes Society. EDEC is the region's premier platform to update attendees on the recent advances in the ever-changing field of diabetes and endocrine diseases.
|MCI Middle East |
United Arab Emirates
Tel: +971 4 311 6300
Fax: +971 4 311 6301